When pharmaceutical companies manage to get highly positive results from clinical trials of one of their more important products, then it almost always has a positive impact on the stock price, and that is what happened with MDCO stock.
Solid BoostThe Medicines Company (NASDAQ:MDCO) announced positive results from the Phase 3 trial of its cholesterol treating medicine Orion 11 and the data from the trials was also presented to the ESC Congress held at Paris. The most important thing about the Phase 3 study is the fact that the product in question managed to meet ...
Read The Full Article On StreetSignals.com
Get the latest stock market news on StreetSignals. Follow public companies and get free stock research reports and stock market analysis data and stock tips.
All content provided by StreetSignals is subject to our Terms Of Use and Disclaimer.